AOD-9604 - AOD9604 (Anti-Obesity Drug 9604) is a synthetic fragment of

AOD-9604

AOD9604 (Anti-Obesity Drug 9604) is a synthetic fragment of human growth hormone (HGH) that targets fat metabolism without raising IGF-1.

Fat Loss
In Stock

1 vial · 5 mg total

Checking availability…

Total Price

฿1300

CardCrypto−5%Revolut · Wise · PayPalEncrypted checkout

Prefer Revolut, Wise or PayPal?

For research & laboratory use only. Not for human consumption.

Shipping: free within Thailand, ฿700 worldwide. Added at checkout. Delivery times & countries

Half-Life

30-60 minutes

Administration Route

Subcutaneous injection

Targeted Fat Breakdown

Activates lipolysis without stimulating IGF-1 or growth

No Glucose Impact

Does not affect blood sugar or insulin sensitivity

Growth Factor Activity

Retains bone-protective effects of HGH C-terminal fragment

Effect Timeline

Start - Week 2

Lipolytic signalling active; fat cell metabolism increases

Week 4

Stubborn fat deposits begin mobilising

Week 8

Visible reduction in body fat %, especially peripherally

Week 12

Sustained fat loss without lean mass loss confirmed

Mechanism of Action

AOD9604 is a modified peptide built from the final amino acids (177-191) of human growth hormone, with a tyrosine added at position 177 for stability. This C-terminal fragment keeps the fat-mobilising (lipolytic) and fat-storage-blocking (anti-lipogenic) actions of intact HGH, yet omits the N-terminal region that triggers IGF-1 release. Because IGF-1 is not stimulated, AOD9604 avoids the anabolic and blood-sugar-raising (diabetogenic) effects of full growth hormone. Research indicates it acts on beta-3 adrenergic receptors in adipocytes, switching on lipolysis and suppressing lipogenesis through a pathway that is independent of the growth-promoting HGH signal.

Scientific Research

1
Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone

Horm Res (2000)

2
Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment

Int J Obes Relat Metab Disord (2001)

3
The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice

Endocrinology (2001)

Why Researchers Choose AOD9604

AOD9604 is studied wherever the goal is to isolate the fat-metabolising action of human growth hormone from its growth-promoting effects. Because the HGH fragment drives lipolysis without raising IGF-1, insulin or glucose, it is a clean tool for fat-metabolism research:

  • Selective adipose-tissue lipolysis without IGF-1 or anabolic confounders
  • Comparative lipolysis pharmacology against intact HGH and the related fragment 176-191
  • Beta-3 adrenergic receptor activity studies in adipocytes
  • Lipogenesis inhibition and fat-cell differentiation research
  • Metabolic syndrome and abdominal-adiposity investigations
  • Long-term safety profiling of lipolytic peptide fragments

Reconstitution and Storage

Reconstitution: use bacteriostatic water (1 to 2ml); swirl gently until the powder fully dissolves, do not shake. After reconstitution: keep refrigerated (2-8°C), use within 28 days, do not freeze, and protect from direct light.

Vial & calculation

Calculate concentration and volume from the labelled amount, your final solution volume and a target amount you provide.

Open calculator for AOD-9604

Current product variants are listed in the calculator. No personal dose is selected for you.

Product FAQs

Research Tools

Dosing Calculator

Concentration & syringe units

Injection Guide

8-step visual protocol

Peptide Finder

Find the right peptide